Ionis Presents Two-year Results From The Phase 2 Open Label Extension Study Of Donidalorsen In Patients With Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has announced positive results from a two-year Phase 2 open-label extension study of its investigational drug, donidalorsen, for patients with hereditary angioedema (HAE). The study showed a sustained reduction in HAE attacks and improved quality of life for patients. Donidalorsen recently received orphan drug designation in the U.S. and is expected to report Phase 3 results in H1 2024.
November 09, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals' stock may see positive movement due to the successful results of the Phase 2 study of donidalorsen. The drug's recent orphan drug designation in the U.S. and the anticipation of Phase 3 results in H1 2024 could also contribute to investor interest.
The positive results from the Phase 2 study of donidalorsen indicate that the drug is effective and safe for patients with HAE. This could lead to increased investor confidence in Ionis Pharmaceuticals and a potential rise in the company's stock price. The recent orphan drug designation in the U.S. for donidalorsen also adds to the drug's potential market value. The anticipation of Phase 3 results in H1 2024 could further drive investor interest.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100